Development of novel NLRP3-XOD dual inhibitors for the treatment of gout. Issue 4 (15th February 2020)

• Record Type: Journal Article
• Authors: Wang, Weiwei; Pang, Jing; Ha, Eun Hee; Zhou, Mengze; Li, Zhubin; Tian, Sheng; Li, Huanqiu; Hu, Qinghua
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 30:Issue 4(2020)
• Publication Date: 2020-02-15
• Subjects: Gout -- Acute gouty arthritis -- Nod-like protein receptor 3 -- Dual inhibitors; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2019.126944
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Gout is a crystalline-related arthropathy caused by the deposition of monosodium urate (MSU). Acute gouty arthritis is the most common first symptom of gout. Studies have shown that NOD-like receptor protein 3 (NLRP3) inflammasome as pattern recognition receptors can be activated by uric acid crystallization, triggering immune inflammation and causing acute gouty arthritis symptoms. Currently, the treatment of gout mainly includes two basic methods: reducing uric acid and alleviating inflammation. In this paper, 22 novel benzoxazole and benzimidazole derivatives were synthesized from deoxybenzoin oxime derivatives. These compounds have good inhibitory effects on NLRP3 and XOD screened by our research group in the early stage. The inhibitory activities of XOD and NLRP3 and their derivatives were also screened. Notably, compound 9b is a multi-targeting inhibitor of NLRP3 and XOD with excellent potency in treating hyperuricemia and acute gouty arthritis.